New York, USA – November 7, 2019 – Creative Biolabs, a dynamic biotech company engaged in customized antibody development for decades, yesterday announced that the precise identification of leucine and isoleucine by mass spectrometry has been unprecedentedly achieved, advancing breakthrough science on protein/antibody sequencing in research, diagnostic, and therapeutic industries.
The discrimination of leucine and isoleucine has long been the key technical difficulties of de novo antibody sequencing. However, Creative Biolabs just took a massive leap forward into the new era of this field, with unchallenged ability to achieve 100% accuracy in antibody sequencing by precisely distinguishing between leucine and isoleucine, based on the proprietary Database Assisted Shotgun Sequencing (DASS) technology.
In the past, traditional de novo antibody sequencing using the Next-Generation Sequencing (NGS) technique could not precisely distinguish leucine and isoleucine due to their unspecific and random distribution, the same molecular mass, and similar chemical property. Researchers could only speculate the possible locations of leucine and isoleucine in an antibody sequence during analysis, which is time-consuming and uneconomical. Therefore, highly efficient and cost-effective sequencing technology is needed to overcome these conventional limits.
Through years of persistent efforts, scientists in Creative Biolabs successfully accomplished the mission impossible, being able to unequivocally distinguish the location of leucine and isoleucine, which enables a genuine sense of 100% accuracy in de novo antibody sequencing for superior functional analysis.
“A valuable breakthrough has never come easily. We all know how hard it is to confidently guarantee our clients 100% accurate results in an antibody sequencing project. This achievement really encouraged us a lot. In the past decade, our scientists have helped Creative Biolabs gain a good reputation through numerous successful cases and constant efforts. We are proud to provide antibody sequencing with 100% accuracy and satisfy our customers’ research needs,” said Dong H. Chen, the CSO of Creative Biolabs, “to precisely identify leucine and isoleucine is just one step along the path, but an important one.”
Highlights of De Novo Antibody Sequencing Services in Creative Biolabs:
• One and the only: Discrimination of Leucine & Isoleucine.
• Sensitive: Full coverage obtained from 50-100 µg of proteins.
• Robust: 100% coverage guaranteed for the VJ and VDJ region.
• High-Throughput: Capable of customizing project with 100, 200, 500 or more antibodies.
• Integrated: Antibody designing, cloning, de novo sequencing and analyzing, as well as in vitro optimization.
About Creative Biolabs
Founded in Shirley, New York, Creative Biolabs is a leading service provider that covers the entire antibody discovery and development process. Featured services include phage display, antibody humanization, engineered antibody production (Fab, scFv, bispecific antibody, sdAb, etc.), stable cell line development, membrane protein production, preclinical in vivo studies, and cGMP-manufacturing. Since the establishment in 2004, Creative Biolabs has grown into a well-recognized contract service provider collaborating with numerous pharmaceutical and biotech companies as well as research laboratories. The scientists in Creative Biolabs are highly specialized with years of experience collaborating with clients all over the world. The high-quality customized services and products from Creative Biolabs have been and will continue to make significant contributions to every antibody discovery and development project.